The stock of Pfizer Inc. (PFE) has gone down by -3.00% for the week, with a -8.36% drop in the past month and a -8.94% drop in the past quarter. The volatility ratio for the week is 1.76%, and the volatility levels for the past 30 days are 1.64% for PFE. The simple moving average for the past 20 days is -5.36% for PFE’s stock, with a -16.75% simple moving average for the past 200 days.
Is It Worth Investing in Pfizer Inc. (NYSE: PFE) Right Now?
The price-to-earnings ratio for Pfizer Inc. (NYSE: PFE) is above average at 71.95x, Company’s 36-month beta value is 0.61.Analysts have differing opinions on the stock, with 11 analysts rating it as a “buy,” 1 as “overweight,” 9 as “hold,” and 0 as “sell.”
The public float for PFE is 5.64B, and currently, short sellers hold a 1.15% ratio of that floaft. The average trading volume of PFE on April 15, 2024 was 42.93M shares.
PFE) stock’s latest price update
The stock price of Pfizer Inc. (NYSE: PFE) has plunged by -1.82 when compared to previous closing price of 26.34, but the company has seen a -3.00% decline in its stock price over the last five trading sessions. Seeking Alpha reported 2024-04-12 that Pfizer has faced numerous challenges, including a decline in COVID-19 vaccine demand and high costs, but the worst is likely priced into the stock. The company is focusing on innovation and has ambitious plans to launch new products and indications, which could drive significant revenue growth. Pfizer’s investment in oncology and the use of AI in drug development are promising, and the company’s valuation suggests upside potential.
Analysts’ Opinion of PFE
Guggenheim, on the other hand, stated in their research note that they expect to see PFE reach a price target of $36. The rating they have provided for PFE stocks is “Buy” according to the report published on February 23rd, 2024.
TD Cowen gave a rating of “Market Perform” to PFE, setting the target price at $32 in the report published on January 04th of the current year.
PFE Trading at -5.21% from the 50-Day Moving Average
After a stumble in the market that brought PFE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.12% of loss for the given period.
Volatility was left at 1.64%, however, over the last 30 days, the volatility rate increased by 1.76%, as shares sank -8.07% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.51% lower at present.
During the last 5 trading sessions, PFE fell by -3.00%, which changed the moving average for the period of 200-days by -29.00% in comparison to the 20-day moving average, which settled at $27.21. In addition, Pfizer Inc. saw -10.18% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PFE starting from Gottlieb Scott, who purchase 3,000 shares at the price of $26.47 back on Dec 15 ’23. After this action, Gottlieb Scott now owns 9,000 shares of Pfizer Inc., valued at $79,401 using the latest closing price.
Gottlieb Scott, the Director of Pfizer Inc., purchase 1,000 shares at $38.58 during a trade that took place back on May 08 ’23, which means that Gottlieb Scott is holding 6,000 shares at $38,580 based on the most recent closing price.
Stock Fundamentals for PFE
Current profitability levels for the company are sitting at:
- 0.06 for the present operating margin
- 0.49 for the gross margin
The net margin for Pfizer Inc. stands at 0.04. The total capital return value is set at 0.02. Equity return is now at value 2.31, with 1.01 for asset returns.
Based on Pfizer Inc. (PFE), the company’s capital structure generated 0.45 points at debt to capital in total, while cash flow to debt ratio is standing at 0.12. The debt to equity ratio resting at 0.81. The interest coverage ratio of the stock is 1.63.
Currently, EBITDA for the company is 10.53 billion with net debt to EBITDA at 7.3. When we switch over and look at the enterprise to sales, we see a ratio of 3.73. The receivables turnover for the company is 5.23for trailing twelve months and the total asset turnover is 0.26. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.91.
Conclusion
In a nutshell, Pfizer Inc. (PFE) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
